source
- Oruka surges as long-acting psoriasis drug shows early promiseA therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.BioPharma Dive · 3mo ago↗ source
- Veradermics soars on positive data for baldness treatmentThe results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medica…BioPharma Dive · 3mo ago↗ source
- Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s nextIntellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and potentially dangerous…